In the Claims

Please make the following amendments to the claims, without prejudice to the filing of future continuing applications.

1. - 3. (Cancel)

4. (AMENDED) A monoclonal antibody specifically reacting with **a peptide having an amino acid sequence of residues 12 to 24 of SEQ ID NO: 2**.

5. (AMENDED) ~~A~~ **The** monoclonal antibody as claimed in Claim 4 which is a mouse IgG.

6. (CANCEL)

7. (AMENDED) A method of assaying the 19P2 ligand or a derivative thereof in a test fluid which comprises using the monoclonal antibody ~~as claimed in Claim 1 or~~ **of** Claim 4 **in an assay, said assay comprising contacting a test fluid sample to be assayed with said monoclonal antibody and detecting ligand in said sample**.

8. (Cancel)

9. (AMENDED) A hybridoma cell producing the monoclonal antibody ~~as claimed in Claim 1 or~~ **of** Claim 4.

10. (Amended) ~~A~~ **The** monoclonal antibody of claim 4, which specifically binds with a peptide having the amino acid sequence of SEQ ID NO: 11.

11. (AMENDED) A method for detecting 19P2 ligand in a sample, comprising **contacting** ~~assaying~~ said sample with a

monoclonal antibody of claim 10 and detecting such **ligand** ~~binding~~.

12. - 13. (Cancel)

14. (AMENDED) A method for detecting 19P2 ligand in a sample, comprising ~~assaying~~ **contacting** said sample with a monoclonal antibody of claim 10 and an antibody which specifically binds to a peptide having the amino acid sequence of SEQ ID NO: 7, **and** detecting such **ligand** ~~binding~~.

15. - 17. (Cancel)

18. (AMENDED) ~~A~~ **The** monoclonal antibody of claim 4, which specifically binds with a peptide having the amino acid sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:12.

19. (AMENDED) ~~A~~ **The** monoclonal antibody of claim 4, which specifically binds with a peptide having the amino acid sequence of amino acid residues 12 to 24 of SEQ ID NO: 1, amino acid residues 12 to 24 of SEQ ID NO: 2, or amino acid residues 12 to 24 of SEQ ID NO: 3.

20. (AMENDED) ~~A~~ **The** monoclonal antibody of claim 4, which specifically binds with a 19P2 ligand peptide, but which does not bind with a peptide having the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 6.

21. (AMENDED) ~~A~~ **The** monoclonal antibody of claim 4, which is P2L-1Ta.

22. - 24. (Cancel)

25. (AMENDED) An isolated hybridoma cell line, said cell line producing the antibody P2L-1Ta~~, P2L-3Ta, P2L-1Ca or P2L-2Ca~~.

26. (AMENDED) ~~A~~ **The** method of claim ~~15~~ **11** for detecting 19P2 ligand in a sample, comprising assaying said sample wherein said 19P2 ligand is attached to a carrier.

27. (AMENDED) ~~A~~ **The** method of claim ~~15~~ **11** wherein ~~a~~ **said** monoclonal antibody is attached to a carrier.

28. (AMENDED) ~~A~~ **The** method of claim ~~15~~ **11** wherein ~~a~~ **said** monoclonal antibody is attached to a detectable signal or label.

29. (AMENDED) ~~A~~ **The** method of claim ~~15~~ **11** which is a sandwich assay.

30. (AMENDED) ~~A~~ **The** method of claim ~~15~~ **11** which is a competitive inhibition assay.

31. (AMENDED) ~~A~~ **The** method of claim ~~15~~ **11** in which one monoclonal antibody is P2L-1Ta~~, P2L-3Ta, P2L-1Ca or P2L-2Ca~~.